Not so puzzling: Actavis, Forest pieces fit strategic gaps
This article was originally published in Scrip
The $25bn merger of brand-name drug marketer Forest Laboratories into generics maker Actavis isn't so puzzling, considering Actavis's increased focus on specialty medicines and the pent-up demand for significant returns for Forest shareholders.
You may also be interested in...
Brent Saunder’s Vesper Healthcare Acquisition Corp. wants to raise up to $460m in a forthcoming IPO to buy companies in health care and medical market niches including wellness.
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.